Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin

Joel Ohana; Uziel Sandler; Orly Devary; Yoram Devary

doi:10.18632/oncotarget.28467

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin

Joel Ohana, Uziel Sandler, Orly Devary and Yoram Devary _

PDF | Full Text | Supplementary Files | How to cite | Press Release

Oncotarget. 2023; 14:688-699. https://doi.org/10.18632/oncotarget.28467

Metrics: PDF 650 views | Full Text 2154 views | ?

Abstract

Joel Ohana1, Uziel Sandler1^,2, Orly Devary1 and Yoram Devary1

1 Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel

2 Department of Bio-Informatics, Lev Academic Center (JCT), Jerusalem 91160, Israel

Correspondence to:

Yoram Devary,

email:

[email protected]

Keywords: Colorectal cancer; KRAS; apoptosis; hormone peptide; endoplasmic reticulum stress

Received: March 29, 2023 Accepted: June 15, 2023 Published: July 01, 2023

Copyright: © 2023 Ohana et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Members of the rat sarcoma viral oncogene (RAS) subfamily KRAS are frequently mutated oncogenes in human cancers and have been identified in pancreatic ductal, colorectal, and lung adenocarcinomas. In this study, we show that a derivative of the hormone peptide Tumor Cell Apoptosis Factor (TCApF), Nerofe^™ (dTCApFs), in combination with Doxorubicin (DOX) substantially reduces viability of tumor cells. It was observed that the combination of Nerofe and DOX downregulated KRAS signaling via miR217 upregulation, resulting in enhanced apoptosis of tumor cells. In addition, the combination of Nerofe and DOX also resulted in activation of the immune system against tumor cells, manifested by an increase in the immunostimulatory cytokines IL-2 and IFN-γ as well as the recruitment of NK cells and M1 macrophages to the tumor site.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28467

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin

Abstract